460 related articles for article (PubMed ID: 26994023)
21. FOXO3a deregulation in uterine smooth muscle tumors.
de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
[TBL] [Abstract][Full Text] [Related]
22. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis.
Basaran D; Usubutun A; Salman MC; Narin MA; Boyraz G; Turkmen O; Comert Kimyon G; Karalok A; Bulbul D; Turan T; Ozgul N; Yuce K
Int J Gynecol Cancer; 2018 Feb; 28(2):233-240. PubMed ID: 29303932
[TBL] [Abstract][Full Text] [Related]
23. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
[TBL] [Abstract][Full Text] [Related]
24. Patterns of Chromosomal Abnormalities that Can Improve Diagnosis of Uterine Smooth Muscle Tumors.
Holzmann C; Markowski DN; VON Leffern I; Löning T; Bullerdiek J
Anticancer Res; 2015 Dec; 35(12):6445-56. PubMed ID: 26637855
[TBL] [Abstract][Full Text] [Related]
25. Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas.
Conconi D; Redaelli S; Lissoni AA; Cilibrasi C; Perego P; Gautiero E; Sala E; Paderno M; Dalprà L; Landoni F; Lavitrano M; Roversi G; Bentivegna A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557274
[TBL] [Abstract][Full Text] [Related]
26. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
27. Patterns of bone morphogenetic protein-2 expression in smooth muscle tumors of the uterine corpus and other uterine tissues.
Fadare O; Renshaw IL; Liang SX
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):352-9. PubMed ID: 21285872
[TBL] [Abstract][Full Text] [Related]
28. TOP2A gene copy number change in breast cancer.
Engstrøm MJ; Ytterhus B; Vatten LJ; Opdahl S; Bofin AM
J Clin Pathol; 2014 May; 67(5):420-5. PubMed ID: 24403186
[TBL] [Abstract][Full Text] [Related]
29. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I
Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613
[TBL] [Abstract][Full Text] [Related]
30. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
[TBL] [Abstract][Full Text] [Related]
31. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
[TBL] [Abstract][Full Text] [Related]
32. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
Meng H; Chen R; Li W; Xu L; Xu L
Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
[TBL] [Abstract][Full Text] [Related]
33. The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.
Rubisz P; Ciebiera M; Hirnle L; Zgliczyńska M; Łoziński T; Dzięgiel P; Kobierzycki C
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845657
[TBL] [Abstract][Full Text] [Related]
34. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Fertil Steril; 2004 Apr; 81(4):1062-6. PubMed ID: 15066464
[TBL] [Abstract][Full Text] [Related]
35. [Progress in clinicopathologic study on uterine smooth muscle tumor of uncertain malignant potential].
Deng ZJ; Guo LN
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):573-6. PubMed ID: 22169655
[No Abstract] [Full Text] [Related]
36. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior.
Giuntoli RL; Gostout BS; DiMarco CS; Metzinger DS; Keeney GL
J Reprod Med; 2007 Nov; 52(11):1001-10. PubMed ID: 18161397
[TBL] [Abstract][Full Text] [Related]
37. POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA.
Nishikawa S; Hayashi T; Uzaki T; Yaegashi N; Abiko K; Konishi I
Georgian Med News; 2023 Oct; (343):119-126. PubMed ID: 38096528
[TBL] [Abstract][Full Text] [Related]
38. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
39. Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2/neu, and survivin.
da Cunha IW; De Brot L; Carvalho KC; Rocha RM; Fregnani JH; Falzoni R; Ferreira Fde O; Aguiar S; Lopes A; Muto NH; Reis LF; Soares FA; Vassallo J
Ann Surg Oncol; 2012 Jun; 19(6):1790-9. PubMed ID: 22203181
[TBL] [Abstract][Full Text] [Related]
40. Loss of dystrophin is common in uterine leiomyosarcoma: a potential biomarker for clinical application.
Vadasz B; Felicelli C; Feng Y; Yin P; Zhang Q; Bulun S; Wei JJ
Hum Pathol; 2023 Apr; 134():85-91. PubMed ID: 36549601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
